These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21182993)

  • 1. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.
    Krupa M; Canamero M; Gomez CE; Najera JL; Gil J; Esteban M
    Vaccine; 2011 Feb; 29(7):1504-13. PubMed ID: 21182993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen.
    Cole G; Ali AA; McErlean E; Mulholland EJ; Short A; McCrudden CM; McCaffrey J; Robson T; Kett VL; Coulter JA; Dunne NJ; Donnelly RF; McCarthy HO
    Acta Biomater; 2019 Sep; 96():480-490. PubMed ID: 31299353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
    Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
    Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.
    Xiao L; Joo KI; Lim M; Wang P
    PLoS One; 2012; 7(11):e48866. PubMed ID: 23139820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
    Simons BW; Cannella F; Rowley DT; Viscidi RP
    Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice.
    Yang D; Holt GE; Velders MP; Kwon ED; Kast WM
    Cancer Res; 2001 Aug; 61(15):5857-60. PubMed ID: 11479226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
    Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
    Knudsen ML; Ljungberg K; Tatoud R; Weber J; Esteban M; Liljeström P
    PLoS One; 2015; 10(2):e0117042. PubMed ID: 25643354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse.
    Guo Q; Wang L; Xu P; Geng F; Guo J; Dong L; Bao X; Zhou Y; Feng M; Wu J; Wu H; Yu B; Zhang H; Yu X; Kong W
    Oncoimmunology; 2020 Nov; 9(1):1841392. PubMed ID: 33224629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
    Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
    PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prokaryotic expression, purification and antigenicity identification of mouse prostate stem cell antigen].
    Dong J; Luo J; Yan J; Zhang L; Gao J; Yu J
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Apr; 32(4):502-6. PubMed ID: 22543130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D.
    Meseda CA; Stout RR; Weir JP
    Viral Immunol; 2006; 19(2):250-9. PubMed ID: 16817767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
    Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
    J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
    Hodge JW; Higgins J; Schlom J
    Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.